Lateral in Medical Technology

Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS

... to KNS-760704 for the treatment of amyotrophic lateral sclerosis (ALS). (Logo: ... by Knopp for the treatment of amyotrophic lateral sclerosis (ALS). The drug is an optical ... over a broad dose range. About ALS Amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's ...

Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program

... molecule in clinical development by Knopp for the treatment of amyotrophic lateral sclerosis (ALS). The drug is an optical enantiomer of a selective, high ... activity of KNS-760704 over a broad dose range. About ALS Amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease, is a rapid, ...

Risks of Delaying ACL Reconstruction in Young Athletes May Be Too High, Study Shows

... factors, a delay in treatment of more than 12 weeks had about a four-fold increase in irreparable medial meniscus tears, an 11-fold increase in lateral compartment chondral injuries and a three-fold increase in patellotrochlear injuries. Issues with instability in the knee were also increased ...

New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring

... (SVV) obtained via an invasive catheter (Flo Trac(R)) in 13 patients. After analyzing data recorded at five points--in the supine position, lateral position, start and end of one-lung ventilation, and in the supine position again--researchers found a significant correlation between PVI and SVV (r ...

AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis

... Goods Administration (TGA) that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded Orphan Status for the treatment of Amyotrophic lateral Sclerosis (ALS). ALS is the most common form of Motor Neuron Disease (MND), also known as Lou Gehrig's disease. AIMSPRO has already achieved ...

Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications

... encompass all neurological disorders, including Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, Multiple Sclerosis, and Amytrophic lateral Sclerosis. We expect the official patents to issue in 2009, and if they do, will have a preliminary patent term that expires in 2023. ...

Neuralstem's Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS

... with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic lateral Sclerosis (ALS). The Company filed an IND (Investigational New Drug) application with the FDA for ALS clinical trials in December, 2008, and has ...

Neuralstem's ALS Trial on Clinical Hold

... with research programs currently underway include: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic lateral Sclerosis (ALS). In pre-clinical work, the company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the ...

Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives

... with three Phase 2 clinical trials ongoing for the treatment of diabetic neuropathy (DN) and one to evaluate its use in the treatment of amyotrophic lateral sclerosis (ALS). We have also advanced our preclinical pipeline and expect to file Investigational New Drug (IND) application for the first of our ...

Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology

... "The technology licensed today will help us to meet those goals." Neuralstem will use this technology in its clinical trial for ALS (Amytrophic lateral Sclerosis, or Lou Gehrig's disease). The company anticipates filing its IND (Investigational New Drug) application with the FDA for the ALS trial in ...

Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)

... Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ or http://www.alsa.org About Amyotrophic lateral Sclerosis (ALS) More than 30,000 Americans have ALS, according to the ALS Association, a nonprofit organization that supports ALS research and ...

ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease

... altered expression of genes and proteins, at the onset of, and throughout the progression of the fatal neurodegenerative disease known as amyotrophic lateral sclerosis (ALS, commonly known as Lou Gehrig's disease). The knowledge generated through this effort will be crucial to the identification of ...

Synapse Biomedical Receives FDA Approval of NeuRx Diaphragm Pacing System (DPS)(TM) For Spinal Cord Injury Breathing Applications

... of successfully implanted patients, visit http://www.synapsebiomedical.com/news/success/ . ALS Clinical Trials Also Underway Amyotrophic lateral Sclerosis (ALS), commonly referred to as Lou Gehrig's disease, is a rapidly progressing, incurable and fatal neuromuscular disease characterized by ...

Brain Stem Cells Can Be Awakened, Say Schepens Scientists

... zone (SVZ). The hippocampus is responsible for learning and memory, while the SVZ is a brain structure situated throughout the walls of lateral ventricles (part of the ventricular system in the brain) and are responsible for generating neurons responsible for smell. So scientists believed ...

Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs

... with growth failure due to severe primary IGF-I deficiency, is currently being investigated in Myotonic Muscular Dystrophy (MMD) and Amyotrophic lateral Sclerosis (ALS), or Lou Gehrig's disease. A Phase 2 trial of IPLEX(TM) in MMD is on-going and a substantial portion of the external costs ...

ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science

... for Brain Science in Seattle, Wash. for in situ hybridization (ISH) services using diseased tissues from a preclinical animal model of amyotrophic lateral sclerosis -- ALS, or Lou Gehrig's disease. ALS is a progressive and fatal neurodegenerative disease with no known cause or cure. Under the terms of ...

Genzyme Announces Presentation of New Positive Data on Carticel(R)

... About Carticel CARTICEL is for autologous use and is indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical ...

Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results

... effect of SB-509 on stem cell mobilization -- Initiate a Phase 2 clinical trial to evaluate SB-509 for the treatment of ALS (Amyotrophic lateral Sclerosis, also known as "Lou Gehrig's disease"). -- Advance ZFP Therapeutic pipeline by initiating Phase 1 clinical trials of ZFP ...

Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis

... biologics and biopharmaceuticals, today provided an update on the IPLEX(TM) Expanded Access Program (EAP) in Italy for the treatment of Amyotrophic lateral Sclerosis (ALS). Since early 2007, the EAP has grown to include 15 physicians and approximately 70 subjects have been enrolled into the program. ...

KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model

... also presented on KineMed's most advanced compound, KM-801, which is expected to enter clinical studies in 2008 for the treatment of Amyotrophic lateral Sclerosis (ALS, or Lou Gehrig's disease). KM-801 is a small-molecule agent, which has been shown to alter microtubule dynamics in nerve cells in ...

ALS TDI Completes Gene Expression Profile of Lou Gehrig's Disease in Mice

... that it has completed the first phase of a comprehensive gene-expression database for ALS with the profiling of the SOD1 mouse model of amyotrophic lateral sclerosis -- ALS, or Lou Gehrig's disease. The second phase, profiling of human samples, is scheduled for completion by February of 2008. This study ...

BSGI Posts Higher Sensitivity than Mammography or MRI for the Detection of Ductal Carcinoma In Situ

... significant difference. Two cases of DCIS (9 percent) were diagnosed only after BSGI demonstrated an occult focus of radiotracer uptake in the contra lateral breast, previously undetected by mammography. There were two false negative BSGI studies. Details about BSGI with the Dilon 6800 Gamma Camera ...

Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease

... neurodegenerative diseases such as Alzheimer's Disease and Amyotrophic lateral Sclerosis in animal models. These findings appear in an article published ... neurological disorders including Alzheimer's Disease and Amyotrophic lateral Sclerosis (ALS), neurodegenerative diseases which have been associated ...

Aeolus Pharmaceuticals Announces Successful Completion of Multiple Dose Safety Study of AEOL 10150

... likely targets for an efficacy study as a protector of healthy cells in radiation therapy in lung cancer and/or head and neck cancer and Amyotrophic lateral Sclerosis ("ALS" or "Lou Gehrig's disease"). Study 102 was a double-blind, randomized, placebo-controlled Phase 1 clinical study to assess the ...

CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies

... by CytRx in December 2006. Orally-administered arimoclomol is currently in clinical evaluation as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). Based on these impressive results, CytRx will begin planning a potential Phase II clinical trial with ...

Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of CERE-120 Demonstrating Improved Motor Function in Parkinson's Patients

... of our products, much like CERE-120, is aimed at unmet neurodegenerative diseases including Parkinson's disease, Alzheimer's disease and Amyotrophic lateral Sclerosis (AML or Lou Gehrig's disease) with the goal of not only improving the symptoms but also preventing progression of the disease." "Through ...

Aeolus Pharmaceuticals' AEOL 10150 Highlighted in Nature Genetics Publication

... a powerful new approach to treat NF1, as well as other cancers. Many common neurodegenerative diseases including Parkinson's disease, Amyotrophic lateral sclerosis (ALS), and Alzheimer's disease are often associated with mitochondrial dysfunction and the overproduction of reactive oxygen species. ...

Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy

... to be safe and well-tolerated in both a single and a multi-dose phase 1 studies. In animal models, the compound has shown promise in Amyotrophic lateral Sclerosis (ALS), protection of healthy cells from radiation therapy, Parkinson's disease, stroke and neurofibromatosis, among other indications. ...

Aeolus Pharmaceuticals' AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation

... to be safe and well-tolerated in both a single and a multi-dose phase 1 studies. In animal models, the compound has shown promise in Amyotrophic lateral Sclerosis (ALS), protection of healthy cells from radiation therapy, Parkinson's disease, stroke and neurofibromatosis, among other indications. ...

Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study

... for various other indications with unmet medical needs, including myotonic muscular dystrophy, retinopathy of prematurity and amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease). About the University of California, San Francisco The University of California, San ...

Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting

... or any electrocardiogram variables. In this open-label, multi-center study, 506 IEED patients with multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's dementia, Parkinson's disease, or injuries such as stroke and traumatic brain injury, were enrolled to ...

Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in Preclinical Studies

... in skeletal muscle mass and strength. In preclinical models, ACE-031 increased skeletal muscle mass and strength in disease models of amyotrophic lateral sclerosis (ALS), muscular dystrophy, glucocorticoid-induced muscle loss and age-related muscle loss (sarcopenia). ACE-031 offers the potential for an ...

Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics

... 11, 2007 in the Journal of Pharmacology And Experimental Therapeutics (J Pharmacol. Exp. Ther. 2007 May 11; [Epub ahead of print]). Amylotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease in the USA, is a progressive and fatal neurological disease that is estimated to affect ...

Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease

... the effect of transplantation of umbilical cord blood mesenchymal stem cells (UCB-MSCs) on glutamate (Glu) levels in plasma and CSF of amyotrophic lateral sclerosis patients and the second observed the effect of umbilical cord blood mesenchymal stem cell transplantation on nervous system function of ALS ...

Fast, Accurate Influenza A/B Antigen Detection

... is 58 percent and specificity is 97 percent. Quidel Corporation, San Diego, Calif., produces the QuickVue Influenza A+B test, a point-of-care lateral flow immunodiagnostic test designed to detect the presence of the influenza A and B virus in a patient nasal wash or nasal swab sample within 10 ...

Point of Care Strep Tests Speed Treatment, Lower Costs

... most popular RADT products are: The ACON Strep A Twist Rapid Test Device (Throat Swab) from ACON Laboratories, Inc. San Diego, Calif., is a lateral flow test in device format, utilizing a patented design to provide convenience to the user. Specimen extraction is performed directly a built-in swab ...